Merck
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme
Corrected: Merck opens billion-dollar US facility to make Gardasil
Merck, Gardasil, Facility (object), Vaccines, Merck ‘s, United States
Merck opens $1B Gardasil manufacturing facility in North Carolina
Merck, Facility (object), Manufacture, Durham, North Carolina
Merck Opens $1 Billion Vaccine Manufacturing Facility in North Carolina
Merck, vaccine manufacturing, Durham, North Carolina, Gardasil, HPV vaccine, pharmaceutical industry, US manufacturing
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Merck Suspends Gardasil Shipments to China, Lowers 2025 Revenue Forecast
Merck, Gardasil, China, revenue forecast, cancer vaccine, shipment suspension
RFK Jr.’s Financial Ties to Gardasil Litigation Spark Conflict-of-Interest Concerns
RFK Jr., Gardasil, Merck, Conflict of Interest, Vaccine Litigation, HHS Secretary Nomination
WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift
WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act
Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal
Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing